New Antiviral Agents for Treatment of Hepatitis C

被引：1

作者：

Egerman, Robert S. ^{[1
,2
]}

机构：

[1] Univ Florida, Coll Med, Dept Obstet & Gynecol, Div Maternal Fetal Med, Gainesville, FL 32610 USA

[2] Univ Florida, Coll Med, Dept Med, Gen Internal Med, Gainesville, FL USA

来源：

CLINICAL OBSTETRICS AND GYNECOLOGY | 2019年 / 62卷 / 04期

关键词：

hepatitis C; HCV; direct-acting antiviral agents; pregnancy; VIRUS-INFECTION; CLEARANCE; UPDATE; ENTRY;

D O I：

10.1097/GRF.0000000000000457

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Between 70 and 170 million people worldwide are infected with hepatitis C virus (HCV) which frequently causes chronic liver disease and cirrhosis. There are several genotypes and many subtypes of HCV. Direct-acting antiviral agents are effective at eradicating HCV in the vast majority of patients, producing much higher cure rates than were seen with interferon and ribavirin regimens only a few years ago. The chapter reviews the epidemiology and virology of HCV infection. Treatment regimens are complex but a straightforward approach to selection of patients, choice of direct-acting antiviral agents and follow-up is presented.

引用

页码：823 / 834

页数：12

共 31 条

[1]

American Association for the Study of Liver Diseases

[2]

Infectious Diseases Society of America, 2018, HCV GUID REC TEST MA

[3]

Andrews RR, 2018, AM FAM PHYSICIAN, V98, P413

[4]

[Anonymous], MDM POLICY PRACT